切换至 "中华医学电子期刊资源库"

中华肺部疾病杂志(电子版) ›› 2017, Vol. 10 ›› Issue (06) : 641 -645. doi: 10.3877/cma.j.issn.1674-6902.2017.06.002

所属专题: 文献

专家论坛

慢性阻塞性肺疾病合并缺血性心脏病的新理念
成孟瑜1, 许建英1,()   
  1. 1. 030032 太原,山西医学科学院·山西大医院呼吸与危重症医学科
  • 收稿日期:2017-10-16 出版日期:2017-12-20
  • 通信作者: 许建英
  • 基金资助:
    山西省青年科技研究基金资助(2014021040-4)

New concept of chronic obstructive pulmonary disease and ischemic heart disease

Mengyu Cheng1, Jianying Xu1()   

  • Received:2017-10-16 Published:2017-12-20
  • Corresponding author: Jianying Xu
引用本文:

成孟瑜, 许建英. 慢性阻塞性肺疾病合并缺血性心脏病的新理念[J]. 中华肺部疾病杂志(电子版), 2017, 10(06): 641-645.

Mengyu Cheng, Jianying Xu. New concept of chronic obstructive pulmonary disease and ischemic heart disease[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2017, 10(06): 641-645.

1
任成山,钱桂生. 慢性阻塞性肺疾病发病机制研究现状与展望[J/CD]. 中华肺部疾病杂志(电子版), 2009, 2(2):104-115.
2
The Global Strategy for the Diagnosis. Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2017, Available from:

URL    
3
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur J Heart Fail, 2016, 18(8):891-975.
4
Vanfleteren LEGW, Spruit MA, Wouters EFM, et al. Management of chronic obstructive pulmonary disease beyond the lungs[J]. Lancet Respir Med, 2016, 4(11):911-924.
5
Chen W, Thomas J, Sadatsafavi M, et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis [J]. Lancet Respir Med, 2015, 3(8):631-639.
6
Onishi K, Yoshimoto D, Hagan GW, et al. Prevalence of airflow limitation in outpatients with cardiovascular diseases in Japan [J]. Int J Chron Obstruct Pulmon Dis, 2014, 9:563-568.
7
Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care[J]. Thorax, 2010, 40(4):956-962.
8
Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD[J]. Chest, 2010, 137(5):1091-1097.
9
Campo G, Guastaroba P, Marzocchi A, et al. Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention[J]. Chest, 2013, 144(3):750-757.
10
Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality[J]. Proc Am Thorac Soc, 2005, 2(1):8-11.
11
Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease[J]. Lancet, 2011, 378(9795):1015-1026.
12
Papaioannou AI, Mazioti A, Kiropoulos T, et al. Systemic and airway inflammation and the presence of emphysema in patients with COPD[J]. Respir Med, 2010, 104(2):275-282.
13
Boschetto P, Beghé B, Fabbri LM, et al. Link between chronic obstructive pulmonary disease and coronary artery disease: Implication for clinical practice[J]. Respirology, 2012, 17(3):422-431.
14
Momiyama Y, Adachi H, Fairweather DL, et al. Inflammation, Atherosclerosis and Coronary Artery Disease[J]. Clin Med Insights Cardiol, 2016, 8(Suppl 3):67-70.
15
Maclay JD, Macnee W. Cardiovascular disease in COPD: Mechanisms[J]. Chest, 2013, 143(3):798-807.
16
Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease[J]. Lancet, 2012, 379(9823):1341-1351.
17
Yanbaeva DG, Dentener MA, Creutzberg EC, et al. Systemic effects of smoking[J]. Chest, 2007, 131(5):1557-1566.
18
Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events[J]. N Engl J Med, 2002, 347(20):1557-1565.
19
Wang RT, Li JY, Cao ZG, et al. Mean platelet volume is decreased during an acute exacerbation of chronic obstructive pulmonary disease[J]. Respirology, 2013, 18(8):1244-1248.
20
Campo G, Fileti L, Valgimigli M, et al. Poor response to clopidogrel:current and future options for its management [J]. J Thromb Thrombolysis, 2010, 30(3):319-331.
21
Aykan AÇ, Gökdeniz T, Boyac F, et al. Assessment of arterial stiffness in chronic obstructive pulmonary disease by a novel method: cardio-ankle vascular index[J]. Herz, 2014, 39(7):822-827.
22
Mills NL, Miller JJ, Anand A, et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk[J]. Thorax, 2008, 63(4):306-311.
23
Bhatt SP, Cole AG, Wells JM, et al. Determinants of arterial stiffness in COPD[J]. BMC Pulm Med, 2014, 14(1):1-7.
24
Mieres JH, Shaw LJ, Arai A, et al. Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: consensus statement from the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association[J]. Circulation, 2005, 111(5):682-696.
25
Raggi P, Shaw LJ, Berman DS, et al. Prognostic value of coronary artery calcium screening in subjects with and without diabetes[J]. J Am Coll Cardiol, 2004, 43(9):1663-1669.
26
Kennedy J, Shavelle R, Wang S, et al. Coronary calcium and standard risk factors in symptomatic patients referred for coronary angiography[J]. Am Heart J, 1998, 135(4):696-702.
27
Williams MC, Murchison JT, Edwards LD, et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality[J]. Thorax, 2014, 69(8):718-723.
28
Özyılmaz S, Alışır MF, Serdar OA, et al. The value of coronary artery calcium score in the early diagnosis of coronary artery disease in patients with stable chronic obstructive pulmonary disease[J]. Anatol J Cardiol, 2016, 16(4):283-289.
29
Nambi V, Chambless L, He M, et al. Common carotid artery intima-media thickness is a good as carotid intima-media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study[J]. Eur Heart J, 2012, 33(2):183-190.
30
Lorenz MW, Schaefer C, Steinmetz H, et al. Is carotid intima media thickness useful for individual prediction of cardiovascular risk Ten-year results from the Carotid Atherosclerosis Progression Study (CAPS)[J]. Eur Heart J, 2010, 31(16):2041-2048.
31
Cao JJ, Arnold AM, Manolio TA, et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all- cause mortality: the Cardiovascular Health Study[J]. Circulation, 2007, 116(1):32-38.
32
Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-analysis[J]. Circulation, 2007, 115(4):459-467.
33
Androulakis AE, Andrikopoulos GK, Richter DJ, et al. The role of carotid atherosclerosis in the distinction between ischaemic and non-ischaemic cardiomyopathy[J]. Eur Heart J, 2000, 21(11):919-926.
34
Amato M, Montorsi P, Ravani A, et al. Carotid intima-media thickness by B-mode ultrasound as surrogate of coronary atherosclerosis: correlation with quantitative coronary angiography and coronary intravascular ultrasound findings[J]. Eur Heart J, 2007, 28(17):2094-2101.
35
Guaricci AI, Arcadi T, Brunetti ND, et al. Carotid intima media thickness and coronary atherosclerosis linkage in symptomatic intermediate risk patients evaluated by coronary computed tomography angiography[J]. Int J Cardiol, 2014, 176(3):988-993.
36
Darabian S, Hormuz M, Latif MA, et al. The role of carotid intimal thickness testing and risk prediction for the development of coronary atherosclerosis[J]. Curr Atheroscler Rep, 2013, 15(3):306.
37
Avşar O, Demir I, Ekiz O, et al. Relationship between the slow coronary flow and carotid artery intima-media thickness[J]. Anadolu Kardiyol Derg, 2007, 7(1):19-23.
38
Ziyrek M, Tayyareci Y, Yurdakul S, et al. Association of mitral annular calcification with endothelial dysfunction, carotid intima-media thickness and serum fetuin-A: an observational study[J]. Anadolu Kardiyol Derg, 2013, 13(8):752-758.
39
Ozuğuz U, Ergün G, Işık S, et al. Association between C-reactive protein, carotid intima-media thick- ness and P-wave dispersion in obese premenopausal women: an observational study[J]. Anadolu Kardiyol Derg, 2012, 12(1):40-46.
40
Iwamoto H, Yokoyama A, Kitahara Y, et al. Airflow limitation in smokers is associated with subclinical atherosclerosis[J]. Am J Respir Crit Care Med, 2009, 179(1):35-40.
41
Schroeder EB, Welch VL, Evans GW, et al. Impaired lung function and subclinical atherosclerosis. The ARIC Study[J]. Atherosclerosis, 2005, 180(2):367-373.
42
Barr RG, Ahmed FS, Carr JJ, et al. Subclinical atherosclerosis, airflow obstruction and emphysema: the MESA Lung Study[J]. Eur Respir J, 2012, 39(4):846-854.
43
van Gestel YR, Flu WJ, van Kuijk JP, et al. Association of COPD with carotid wall intima-media thickness in vascular surgery patients[J]. Respir Med, 2010, 104(5):712-716.
44
Köseoğlu C, Kurmuş Ö, Ertem AG, et al. Association between carotid intima-media thickness and presence of coronary artery disease in chronic obstructive pulmonary disease patients[J]. Anatol J Cardiol, 2016, 16(8):601-607.
45
Cazzola M, Rogliani P, Matera MG. Cardiovascular disease in patients with COPD[J]. Lancet Respir Med, 2015, 3(8):593-595.
46
Cazzola M, Calzetta L, Matera M G, et al. Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients[J]. Respir Med, 2015, 109(8):1019-1025.
[1] 马锦芳, 何正光, 郑劲平. 盐酸氨溴索雾化吸入治疗慢性阻塞性肺疾病黏痰症患者的疗效和安全性分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 568-574.
[2] 程炜炜, 张青, 张诚实, 冯契靓, 陈荣荣, 赵云峰. 全身免疫炎症指数与慢性阻塞性肺疾病急性加重期病情严重程度相关性分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 580-584.
[3] 杨万荣, 任治坤, 时新颍. 沙丁胺醇雾化吸入脾多肽治疗AECOPD的疗效分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 609-612.
[4] 赖乾德, 吕相琴, 蔺洋, 刘媛梅, 赵春艳, 李琦. 肝素结合蛋白对慢性阻塞性肺疾病预后预测分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 613-616.
[5] 王微, 丁霖, 陈茜, 呼延欣, 闫蓓. 综合治疗对慢性阻塞性肺疾病的疗效及转归影响分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 621-624.
[6] 方晓玉, 王婷, 赵珊, 陈锋. HALP指数对AECOPD并发呼吸衰竭患者ICU结局的预测意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 639-641.
[7] 郭少琳, 郭建英, 左秀萍, 高苗. 慢性阻塞性肺疾病康复训练依从性影响因素分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 652-654.
[8] 白若靖, 郭军. 维生素D对肺部疾病临床意义的研究进展[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 659-662.
[9] 孔令梅, 徐晓媛, 马丽颖. 慢性阻塞性肺疾病认知衰弱危险因素及预后分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 407-410.
[10] 徐艳, 江秀娟, 王超, 江圆满. 股直肌剪切波弹性成像对COPD并发肌少症的诊断意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 454-457.
[11] 黄映兰, 骆丽萍, 郭慧玲, 袁麟标. 慢性阻塞性肺疾病糖皮质激素治疗反应性的影响因素分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 469-471.
[12] 杨坤, 赵景成, 吴永强. 无创呼吸机在慢性阻塞性肺疾病并发呼吸衰竭救治的临床分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 481-483.
[13] 宋素莉, 贺英华, 陈丽娟. COPD并发吸入性CAP危险因素及病原菌分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 264-267.
[14] 陈婷婷, 李春娟. 经鼻高流量湿化氧疗治疗AECOPD伴Ⅱ型呼吸衰竭的临床分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 276-279.
[15] 周文欢, 杨黎. AECOPD低钠血症发生风险及预测因素分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 313-315.
阅读次数
全文


摘要